RAPT Therapeutics (NASDAQ:RAPT) shares hit a new 52-week high on Thursday . The company traded as high as $42.44 and last traded at $38.48, with a volume of 3552 shares. The stock had previously closed at $36.75.
A number of equities research analysts have weighed in on RAPT shares. UBS Group upped their price objective on shares of RAPT Therapeutics from $26.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. Wells Fargo & Co started coverage on shares of RAPT Therapeutics in a report on Monday, November 25th. They issued an “outperform” rating and a $33.00 price objective on the stock. Finally, BMO Capital Markets started coverage on shares of RAPT Therapeutics in a report on Monday, November 25th. They issued an “outperform” rating and a $35.00 price objective on the stock.
The stock has a fifty day moving average price of $27.11.
RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Wednesday, December 11th. The company reported ($12.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($6.15) by ($6.26).
In other news, major shareholder Group Ii Lp Column purchased 625,000 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were purchased at an average price of $14.49 per share, for a total transaction of $9,056,250.00. Also, CEO Brian Russell Wong purchased 25,000 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were purchased at an average price of $14.49 per share, for a total transaction of $362,250.00. In the last 90 days, insiders acquired 651,600 shares of company stock worth $9,441,684.
RAPT Therapeutics Company Profile (NASDAQ:RAPT)
RAPT Therapeutics, Inc, a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases.
Recommended Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.